Hepatocyte growth factor inhibits tubular epithelial­myofibroblast transdifferentiation by suppression of angiotensin II via the JAK2/STAT3 signaling pathway.

Tubular epithelial­myofibroblast transdifferentiation (TEMT) is important in the development of chronic renal failure. The present study investigated whether hepatocyte growth factor (HGF) inhibits TEMT, and whether this function may be associated with the inhibition of angiotensin II (AngII) and the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. Human HK­2 kidney proximal tubular cells were divided into 4 groups and treated with AngII (1x10­6 M), HGF (8x10­3 M), AngII plus HGF or control conditions, followed by an assessment of apoptosis induction and the expression levels of α­smooth muscle actin (α­SMA), which is a marker of TEMT. as well as the activation level of JAK2, phosphorylated (p)­JAK2, STAT3 and p­STAT3 signaling pathways. In HK­2 cells, α­SMA mRNA and protein expression levels increased following treatment with AngII, however, decreased expression was observed following exposure to HGF. HGF counteracted the AngII­induced increase in the expression of α­SMA in HK­2 cells. Similar expression profiles were observed for the phosphorylated forms of JAK2 and STAT3, indicating the possible involvement of this signaling pathway. The results demonstrated that treatment of cells with AngII was associated with the induction of apoptosis when compared with the control. By contrast, treatment with HGF attenuated AngII­induced apoptosis. The results suggested that HGF may inhibit TEMT by inhibiting AngII through the JAK2/STAT3 signaling pathway in HK­2 cells and HGF may prevent apoptosis induced by AngII. The present study provides a basis for understanding the mechanisms involved in the inhibition of TEMT by HGF, which requires further investigation.

[The relationship between hyperuricaemia and clinic pathology of IgA nephropathy].

OBJECTIVE: To analyze the correlation between the level of serum uric acid and the clinical and pathological features of IgA nephropathy. METHODS: Totally 148 patients diagnosed as IgA nephropathy by renal biopsy in our hospital from January 2007 to December 2010 were divided into hyperuricaemic group (41 cases) and non-hyperuricaemic group (107 cases) according to the level of serum uric acid. The clinical parameters and renal pathology grade were compared. RESULTS: There were significant differences between hyperuricaemic group and non-hyperuricaemic group in the incidences of hypertension (63.4% vs 38.3%), disease duration [(18.90 ± 10.12) months vs (9.46 ± 3.91) months] and body mass index [(22.81 ± 3.60) kg/m(2) vs (15.32 ± 2.54) kg/m(2)] (all P < 0.05), while no differences in age and sex (both P > 0.05). The blood urea nitrogen (BUN) [(8.93 ± 4.28) mmol/L vs (5.21 ± 2.18) mmol/L], creatinine (Cr) [(155.96 ± 107.72) µmol/L vs (79.52 ± 40.01) µmol/L], serum triglycerides [(2.11 ± 1.06) mmol/L vs (1.86 ± 1.20) mmol/L] and 24-hour urine protein amount [(4328.16 ± 1434.25) mg/24 h vs (2885.10 ± 1388.15) mg/24 h] were significantly different between the two groups (all P < 0.05). The percentage of Lee's grade I + II in hyperuricaemic group was 12.2%, and IV + V grade was 39.0%, while percentage of Lee's grade I + II in non-hyperuricaemic group was 25.2%, and IV + V grade was 16.9% (P < 0.05). Tubulointerstitial lesions (TIL) grade III + IV was more in hyperuricaemic group, which was 68.3%, while TIL grade II was more in non-hyperuricaemic group, which was 76.6%. Renal artery damage grade II + III was more in hyperuricaemic group, which was 73.2%, while renal artery damage grade 0 + I was more in non-hyperuricaemic group, which was 69.2%. CONCLUSIONS: The level of serum uric acid was related with 24-hour urine protein amount, blood pressure and kidney function in IgA nephropathy, and Lee's grade, TIL grade and renal artery damage grade were severe in hyperuricaemic group.